Management of trypanosomiasis and leishmaniasis

British Medical Bulletin

Volumn 104, Issue 1, 2012, Pages 175-196

  Barrett, Michael P ^a   Croft, Simon L ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

antiprotozoal drug development; antiprotozoal drug treatment; Chagas disease; human African trypanosomiasis; leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; BENZOXABOROLE; DIAMIDINE DERIVATIVE; EFLORNITHINE; FEXINIDAZOLE; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM; SURAMIN; UNCLASSIFIED DRUG; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; BENZAMIDE DERIVATIVE; BORON DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; SCYX 7158; TRIAZOLE DERIVATIVE;

AFRICAN TRYPANOSOMIASIS; ANEMIA; CHAGAS DISEASE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; URTICARIA; VISCERAL LEISHMANIASIS; AFRICA; DRUG COMBINATION; EPIDEMIOLOGY; INDIA; ORAL DRUG ADMINISTRATION; TRYPANOSOMIASIS, AFRICAN;

ADMINISTRATION, ORAL; AFRICA; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BENZAMIDES; BORON COMPOUNDS; CHAGAS DISEASE; DRUG THERAPY, COMBINATION; HUMANS; INDIA; LEISHMANIASIS; NITROIMIDAZOLES; PENTAMIDINE; TRIAZOLES; TRYPANOSOMIASIS, AFRICAN;

EID: 84871188045     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/lds031     Document Type: Review

References (45)

1. Stuart K, Brun R, Croft S et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 2008;118:1301-10.
2. El-Sayed NM, Myler PJ, Blandin G et al. Comparative genomics of trypanosomatid parasitic protozoa. Science 2005;309:404-9.
3. Frearson JA, Wyatt PG, Gilbert IH et al. Target assessment for antiparasitic drug discovery. Trends Parasitol 2007;23:589-95.
4. Jacobs RT, Nare B, Phillips MA. State of the art in African trypanosome drug discovery. Curr Top Med Chem 2011;11:1255-74.
5. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006;61:223-74.
6. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;21:334-59.
7. Reithinger R, Dujardin J-C, Louzir H et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96.
8. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nature Rev Microbiol 2007;5:S7-16.
9. Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 2011;17:1478-83.
10. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-26.
11. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin b for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24.
12. Sundar S, Chakravarty J, Agarwal D et al. Single-dose liposomal Amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12.
13. Berman JD, Badaro R, Thakur CP et al. Efficacy and safety of liposomal amphotericin B (Ambisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998;76:25-32.
14. Sundar S, Jha TK, Thakur CP et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81.
15. Hailu A, Musa A, Wasunna M et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in east africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010;4:e709.
16. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
17. Sundar S, Sinha PK, Rai M et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377:477-86.
18. Gonzalez U, Pinart M, Rengifo-Pardo M et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009;CD004834.
19. Gonzalez U, Pinart M, Reveiz L et al. Interventions for old world cutaneous leishmaniasis. Cochrane Database Syst Rev 2008;CD005067.
20. Gonzalez U, Pinart M, Reveiz L et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010;51:409-19.
21. Ben Salah A, Buffet PA, Morizot G et al. WR279,396, a third generation aminoglycoside ointment for the treatment of leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009;3:e432.
22. Lessa HA, Machado P, Lima F et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001;65:87-9.
23. Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the tlr7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis 2009;3:e491.
24. Barrett MP, Burchmore RJ, Stich A et al. The trypanosomiases. Lancet 2003;362:1469-80.
25. Brun R, Blum J, Chappuis F et al. Human African trypanosomiasis. Lancet 2010;375:148-59.
26. Vanhollebeke B, Pays E. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol Microbiol 2010;76:806-14.
27. Barrett MP, Boykin DW, Brun R et al. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 2007;152:1155-71.
28. Chappuis F, Loutan L, Simarro P et al. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 2005;18:133-46.
29. Paine MF, Wang MZ, Generaux CN et al. Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs 2010;11:876-83.
30. Voogd TE, Vansterkenburg EL, Wilting J et al. Recent research on the biological activity of suramin. Pharmacol Rev 1993;45:177-203.
31. Alsford S, Eckert S, Baker N et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 2012;482:232-6.
32. Burri C, Nkunku S, Merolle A et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000;355:1419-25.
33. Rodgers J, Jones A, Gibaud S et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis. 2011;5:e1308.
34. Burri C, Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 2003;90(Suppl. 1):S49-52.
35. Vincent IM, Creek D, Watson DG et al. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 2010;6:e1001204.
36. Priotto G, Kasparian S, Mutombo W et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009;374:56-64.
37. Brun R, Don R, Jacobs RT et al. Development of novel drugs for human African trypanosomiasis. Future Microbiol 2011;6:677-91.
38. Torreele E, Bourdin Trunz B et al. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 2010;4:e923.
39. Jacobs RT, Nare B, Wring SA et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011;5:e1151.
40. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402.
41. Le Loup G, Pialoux G, Lescure FX. Update in treatment of Chagas disease. Curr Opin Infect Dis 2011;24:428-34.
42. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 2011;106:641-5.
43. Pinazo MJ, Espinosa G, Gá llego M et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010;82:583-7.
44. McKerrow JH, Doyle PS, Engel JC et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009;104(Suppl. 1):263-9.
45. Chatelain E, Ioset Jr. Drug discovery and development for neglected diseases: the DNDi model. Drug Des Dev Ther 2011;5:175-81.